Please assess the completion status of the following clinical trial:

Trial Title: Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age with histologically confirmed solid tumor carcinomas (except lung) or multiple myeloma~* Radiographic evidence of 1 or more bone lesions or lytic lesion in myeloma~* Currently receiving IV bisphosphonates~* Urinary N-Telopeptide (uNTx) greater than 50 nM BCE/mM creatinine~* Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2~Exclusion Criteria:~* More than 2 prior skeletal related events (SRE)~* Known brain metastases~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw~* Active dental or jaw conditions which requires oral surgery~* Non-healed dental/oral surgery~* Prior administration of AMG 162~* Evidence of impending fracture in weight bearing bones~* Pregnancy or breastfeeding. Subjects must be surgically sterile, postmenopausal, or must agree to use effective contraception during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Bisphosphonates q 4 weeks (Type: ACTIVE_COMPARATOR): This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
- 180 mg AMG 162 (SC) q 12 weeks (Type: EXPERIMENTAL): This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
- 180 mg AMG 162 (SC) q 4 weeks (Type: EXPERIMENTAL): This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).